Core Scientific CEO Trades Shift from Selling to Performance‑Based Buying Amid 126% YoY Surge

Insider Activity Spotlight: Core Scientific Inc.

Performance‑Driven Share Surge On March 31, 2026, CEO Sullivan Adam Taylor completed a performance‑based restricted stock unit (PSU) grant that converted into 741,545 shares of Common Stock. Although the transaction was executed at no cash price, the effective settlement of the PSUs reflects that Core Scientific has met its aggressive performance thresholds for the 2025 fiscal year. This is a bullish signal for shareholders, indicating that the company’s leadership is rewarded in line with long‑term value creation rather than short‑term trading. At the same time, the company withheld 315,307 shares to cover tax obligations on the vested PSUs, a routine but noteworthy step that underscores the scale of the grant.

CEO’s Transaction Pattern – A Cautious Optimist Taylor’s historic trading record shows two large sales in late January 2026, each of roughly 274,500 shares at $18.79, bringing his holdings to just over 4.13 million shares. Those sales occurred after a period of significant share‑holding and a recent surge in Core’s market valuation, suggesting a strategic divestiture rather than a panic sale. The March 31 PSU buy, contrasted with his earlier sells, signals a shift toward long‑term commitment: the CEO is now buying back into the company’s stock when performance milestones are met, a behavior that aligns with investor expectations for insider confidence. Historically, Taylor’s trades have been executed at or near market price, with minimal price distortion, indicating a disciplined approach that respects market integrity.

Implications for Investors The timing of the PSU settlement—just before the company’s annual proxy filing—could boost investor sentiment. A PSU vesting tied to performance metrics such as revenue growth, R&D milestones, or market expansion offers a clear roadmap for future earnings. Combined with the company’s 52‑week high of $23.63 and a strong yearly gain of 126%, the CEO’s buy signals that the leadership believes the stock is undervalued at the current $15.30 close. However, the company’s negative price‑earnings ratio of –18.68 and a 4.78% weekly decline remind investors that Core remains in a high‑growth, high‑risk niche within IT, where valuation swings are common.

Company‑Wide Insider Activity Context While Taylor’s activity dominates the headline, other insiders such as Todd Duchene have shown a mixed buying and selling pattern, reflecting the typical ebb and flow of executive portfolios. The overall insider activity is modest compared to the CEO’s large transactions, reinforcing that Taylor’s moves are the primary signal for the company’s strategic direction. The recent 144 notice on April 1, 2026, indicating the sale of 140,000 shares by the company itself, further points to a broader capital‑market strategy aimed at liquidity and potential future capital raises.

Forward‑Looking Takeaway For investors, the confluence of a performance‑based PSU vesting, the CEO’s historical buying‑after‑selling pattern, and the company’s robust year‑to‑date performance suggests a cautiously optimistic outlook. The core IT and blockchain focus positions Core Scientific to capitalize on the next wave of digital infrastructure demand. Yet, the negative PE ratio and recent price decline warrant vigilance. Monitoring future performance criteria and any additional insider transactions will provide further insight into whether Taylor and his peers remain committed to steering the company through its next growth phase.